Opdivo for HCC – pro

Nivolumab is still an experimental therapy for HCC. The Checkmate 040  study showed a 16% ORR, as presented in abstract form. There are not full study publications and no guideline reocmmendatins and clinical trials of this drug for HCC are ongoing to define repsonse rates, dose and schedule. a phase III randomized trial of nivolumab versus sorafenib has been launched in the frontline setting.3 The trial, which is seeking to enroll 726 patients, has an estimated primary completion date of July 2017.
  1. Sangro B, Melero I, Yau T, et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-escalation cohorts from the phase 1/2 CheckMate 040 study. Presented at: 10th Annual International Liver Cancer Association Conference; September 9-11, 2016; Vancouver, Canada. Abstract O-019.
  2. El-Khoueiry AB, Sangro B, Cheung Yau T, et al. Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of the CheckMate-040 dose escalation study. J Clin Oncol. 2016;34(suppl; abstr 4012).

Categories

Blog Archives